^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KAND567

    i
    Other names: KAND567, AZD8797, KAN0440567, KAND 567, AZD-8797, KAN-0440567
    Associations

    News

    Trials
    Company:
    Kancera
    Drug class:
    CX3CR1 antagonist
    Associations

    News

    Trials
    6ms
    KANDOVA: A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=18, Completed, Kancera AB | Active, not recruiting --> Completed
    Trial completion
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD
    |
    carboplatin • KAND567
    1year
    KANDOVA: A Study to Evaluate the Safety of KAND567, in Combination with Carboplatin Therapy, in Women with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=18, Active, not recruiting, Kancera AB | Recruiting --> Active, not recruiting | Phase classification: P2 --> P1/2 | N=30 --> 18 | Trial completion date: Jun 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
    Enrollment closed • Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD
    |
    carboplatin • KAND567
    1year
    A Small Molecule Antagonist of CX3CR1 (KAND567) Inhibited the Tumor Growth-Promoting Effect of Monocytes in Chronic Lymphocytic Leukemia (CLL). (PubMed, Cancers (Basel))
    Our data suggest that the CX3CR1/CX3CL1 axis is activated in CLL and may contribute to the NLC-driven growth-promoting effects of CLL cells. KAND567, which is in clinical trials in other disorders, should also be explored in CLL.
    Journal
    |
    CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • ANXA5 (Annexin A5) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
    |
    CD19 expression
    |
    KAND567
    1year
    Dual Targeting of CX3CR1 and PARP in Models of High-Grade Serous Ovarian Carcinoma. (PubMed, Cancers (Basel))
    While the exact mechanisms determining the nature of the PARPis and AZD8797 interaction remain to be uncovered, our data indicate that, in a subset of models, selected PARPis strongly synergize with the inhibition of CX3CR1, suggesting a potential therapeutic opportunity.
    Journal
    |
    PARP1 (Poly(ADP-Ribose) Polymerase 1) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
    |
    Lynparza (olaparib) • Zejula (niraparib) • Rubraca (rucaparib) • veliparib (ABT-888) • KAND567
    2years
    KANDOVA: A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Kancera AB
    New P2 trial • Combination therapy
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD
    |
    carboplatin • KAND567
    over5years
    A novel CX3CR1 inhibitor AZD8797 facilitates early recovery of rat acute spinal cord injury by inhibiting inflammation and apoptosis. (PubMed, Int J Mol Med)
    Another batch of rats (subdivided into sham, injury model, AZD8797 and methylprednisolone groups) were used to evaluate locomotive recovery with a Basso Beattie Bresnahan score. The effect of AZD8797 was mediated by suppressing apoptosis, necrosis and inflammatory responses, as assessed by WB/ELISA and morphological examinations. The current study has demonstrated that AZD8797 can effectively block overwhelming inflammation, apoptosis and necrosis after SCI and facilitate early recovery of locomotive function.
    Preclinical • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3)
    |
    KAND567 • methylprednisolone oral